Gestalt Diagnostics and Flagship Biosciences Announce Strategic Relationship to Deliver Integrated Image Analysis for PD-L1 Testing

Gestalt Diagnostics and Flagship Biosciences announced their collaboration in the development of an integrated workflow for pathologists to access Flagship’s Image Analysis services for digital images to support PD-L1 testing. The companies are providing a more efficient diagnostic process by engaging in a shared service to add Flagship’s computational services to Gestalt’s digital pathology solution, PathFlow.

Read More: Blockchain Needs Quantum-Resistant Technology Says Renowned Cryptographer David Chaum

“Our relationship with Flagship Biosciences, and the resulting automated and streamlined workflow for PD-L1 cases is another step forward in our digital platform,” says Gestalt COO & Chief Strategy Officer, Lisa-Jean Clifford.  “This new relationship is giving pathologists access to the automation and tools that will continue to increase their efficiency, minimizing the manual steps in their case work. We are pleased to partner with Flagship Biosciences to integrate their machine learning/AI tools to provide cancer marker detection.”

Read More: Chainalysis Launches On-Demand Compliance Support for ERC-20 Tokens

“Our goal is to provide a more streamlined workflow for pathologists as well as provide more insight for oncologists through our computational services. We’re pleased to be partnering with Gestalt to advance the state of diagnostics through the use of image analysis,” said Trevor Johnson, Flagship Bioscience’s CEO.

Gestalt’s PathFlow™ users will have the ability to directly request the PD-L1 image analysis service from within the interface. A consistent PD-L1 report and images are returned and loaded into the case file for final review.

Read More: Amazon Brings AI Performance to the Cloud with NVIDIA T4 GPUs